An interdisciplinary health science project is to be centered on a Novel cancer prodrug therapy project
The School of Chemistry is proud to announce a collaborative project with Morvus. Morvus Technology Limited is a pharmaceutical company specialising in the discovery and commercialisation of novel drugs for the oncology market. The Company is technology-rich and has the capability to generate revenue by out-licensing a number of early-stage products whilst simultaneously progressing selected candidates through clinical development and into patient trials. The Carmarthen based company is pleased to have obtained a Knowledge Economy Skills Scholarships (KESS) award for a PhD studentship in conjunction with Dr C Gwenin. The funding for the project was obtained from a major European Convergence programme led by Bangor University on behalf of the HE sector in Wales with the financial support of Morvus.
The interdisciplinary project centres around the use of a directed enzyme-prodrug therapy which is a treatment based on the targeted delivery of enzymes directly to the malignant growth, where the enzymes convert a harmless prodrug into a cytotoxic drug that preferentially kills malignant cells. This approach overcomes the serious systemic side effects of current Chemotherapy which will provide a major advancement in the treatment of cancer and the preventative spread of cancer. The exploitation of the resulting methodology is relevant to all forms of prodrugs.
School of Chemistry, Bangor University, Bangor, Gwynedd, LL57 2UW, UK
Direct Line: 0044 1248 383741 email: email@example.com